National and Kapodistrian University of Athens
Μελέτη και κλινική αξιολόγηση νέων μοριακών δεικτών καρκίνου του μαστού
Abstract
dc:descriptionRecent reports have included PALB2 (Partner and localizer of BRCA2) in the growinglist of hereditary cancer genes. PALB2 is located in the chromosome region 16p12.1and consists of 13 exons transcribing approximately 3.5Kb mRNA, which encodes aprotein of 1186 amino acids. Exons 4 and 5 are much larger than all the others (65%of the coding area). Its deleterious mutations confer a moderate breast cancer risk inheterozygotes and Fanconi anemia in biallelic mutation carriers (hence its other name:FANCN) and are rare: 1-2 % of BRCA negative breast cancer patients in mostpopulations. PALB2 protein co-localizes with BRCA2 and BRCA1 in nuclearstructures and enables error-free homologous recombination DNA repair of doublestrandedbreaks. This important contribution could be severely diminished, not onlyby mutations, but also by epigenetic mechanisms such as promoter CpG islandmethylation. In such a case, patients could benefit from therapeutic treatment withPARP inhibitors.The aim of the study was: A) The genetic analysis of the PALB2 gene foridentification of mutations in DNA from peripheral blood samples of patients withfamiliar breast and ovarian cancer B) the expression analysis of PALB2 gene in tissuesamples of patients with sporadic breast cancer for identification of epigeneticsmechanisms that might silence gene’s expression.MethodsFor the genetic analysis of the two large exons of the gene (exon 4 and 5), a PTTnovel methodology was developed (Protein Truncation Test) and for the rest smallexons of the gene the HRMA methodology was applied. The results were confirmed with DNA Sequencing. In addition the gene was also tested for large rearrangementswith MLPA analysis.For the expression analysis of PALB2 gene, pyrosequencing methodology forstudying the DNA methylation of the gene’s promoter and RT- qPCR with a TaqManprobe in the Light Cycler for the quantification of PALB2 mRNA transcripts weredeveloped and validated. Then, there was an effort to confirm the expression resultswith immunohistochemistry (IHC) with a polyclonal PALB2 antibody During genetic analysis of 57 samples (among them 15 samples of medullary breastcancer) the missence mutations Q599R was found in two samples, the synonymousmutation T1100T was found in five samples and an intronic new polymorphism inone sample. The MLPA analysis was negative in all samples. No deleterious PALB2mutation was detected. This was the first study investigating PALB2 mutations in therare medullary breast cancer.During the DNA methylation analysis of the PALB2 promoter all specimens werefound to be negative therefore, rendering DNA methylation as an unlike mechanismfor its expression silencing. In RT-qPCR four samples had no PALB2 expression. Thefact that PALB2 gene was not expressed in four specimens was examined further withimmunohistochemistry experiments. They have shown only cytoplasmic staining ofthe PALB2 protein with no nuclear staining; probably due to defective antibody, thusit was not possible to draw any conclusion for PALB2 protein expression profile ofthose four samples. The average value of the copies was 7,23×104 copies/μg of totalRNA, while the median value was 1,34×104 copies/μg (range 3,51×10 to 1,23×106copies/μg). The results were compared with clinical and histopathological data (tumorsize, grade, lymph node involvement, hormone receptors, C-ERBB2 overexpression)but no significant statistical correlation was found. So far, PALB2 expression does notseem be a promising prognostic and predictive biomarker for sporadic breast cancer.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Poumpouridou, Nikoleta
- Πουμπουρίδου, Νικολέτα
Subjects
dc:subject × 19- Μεθυλίωση DNA
- Ακυσιδωτή αντίδραση πολυμεράσης
- Πρόωρος τερματισμός προτεϊνοσύνθεσης
- PALB2 (partner and localizer of BRCA2)
- PTT (protein truncation test)
- HRMA (high resolution melting curve analysis)
- MLPA (multiplex ligationdependent probe amplification)
- Pyrosequencing
- DNA methylation
- reverse transcriptase- quantitive PCR
- RT- qPCR
- Φυσικές Επιστήμες
- Βιολογία
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Natural Sciences
- Biological Sciences
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44053